This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040\_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040\_Nifedipine 40 mg/day (40 mg once daily) in patients with essential hypertension who are not at target blood pressure by BAYA1040\_Nifedipine 40 mg once daily treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
352
BAYA1040\_Nifedipine 40mg twice daily (BID)
BAYA1040\_Nifedipine 40mg once daily (OD)
Unnamed facility
Hirosaki, Aomori, Japan
Unnamed facility
Kamagaya, Chiba, Japan
Unnamed facility
Efficacy changes measured by sitting diastolic blood pressure (DBP)
Time frame: Up to 8 weeks
Efficacy changes measured by sitting systolic blood pressure (SBP)
Time frame: Up to 8 weeks
Achievement rate: Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines
Time frame: Up to 8 weeks
Responder rate: Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP
Time frame: Up to 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Asahikawa, Hokkaido, Japan
Unnamed facility
Asahikawa, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
...and 12 more locations